In late 2019, COVID-19 came as a bolt from the blue and begun to spread across globally. Due to an increase in business opportunities in this field, many people have started to invest in businesses that produce and market biocidal products. For the old players that are familiar with the business, they may face some challenges such as:
As for the new players who have just started their journey in this field, they are facing more challenges that includes:
New players may also depend on the advice of external laboratories or consultants to select the efficacy tests that are suitable for their products. If an external laboratory or consultant provides incorrect information, the manufacturers may end up spending more money and time. This happens more often that you think.
Unfortunately, there are many new players that are unaware of the efficacy and/or analysis tests required for their newly developed disinfectant and may sell them without fulfilling the requirements. Did you know that Singapore’s Health Sciences Authority (HSA) has withdrawn many products due to safety issues as well? Have a quick read here to know more about this. Cases as such will eventually cause a huge loss to the product owner.
TECOLAB was established in 2020 during the pandemic. The main objective of establishing TECOLAB is to provide antimicrobial product manufacturers—whether local or international—with solutions to their challenges and an ideal efficacy testing strategy to enhance product uniqueness and popularity in the market.
TECOLAB was founded by Dr Marven Lee. He completed his PhD in Science from the University of Adelaide in 2016 and have always had a vision to perpetually contribute to the infection control field globally. His previous working experience was in another commercial laboratory in Malaysia as the Head of Microbiology Department. During his time there, he was involved in performing method verification on different European Standard efficacy methods and putting them under their ISO 17025 accreditation scope. He left the company in 2019 to focus more on the challenges faced by many antimicrobial product manufacturers. During the COVID-19 outbreak, he gathered investors with the same visions to establish TECOLAB. Besides providing solutions to the new and old players in the infection control field, Dr Marven aspires to use his available resources for the following:
By gathering a team of one PhD holder, 4 Master’s and 3 Bachelor’s degree graduates, TECOLAB achieved ISO 17025 accreditation in only 6 months—all within a year of establishment. With our scientifically strong ensemble, we are able to design suitable tests using our extensive knowledge and experience in this field. We strive to provide our prospects and customers with only the best quality service.